A Role for Low Density Lipoprotein Receptor-Related Protein 1 in the Cellular Uptake of Tissue Plasminogen Activator in the Lungs
详细信息 查看全文
- 作者：Swan Lin ; Jennifer Racz ; Melissa F. Tai ; Kristina M. Brooks…
- 关键词：plastic bronchitis ; receptor mediated endocytosis ; therapeutic proteins
- 刊名：Pharmaceutical Research
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：33
- 期：1
- 页码：72-82
- 全文大小：4,100 KB
- 参考文献：1.Heath L, Ling S, Racz J, Mane G, Schmidt L, Myers JL, et al. Prospective, longitudinal study of plastic bronchitis cast pathology and responsiveness to tissue plasminogen activator. Pediatr Cardiol. 2011;32(8):1182–9.PubMed PubMedCentral CrossRef
2.Racz J, Mane G, Ford M, Schmidt L, Myers J, Standiford TJ, et al. Immunophenotyping and protein profiling of Fontan-associated plastic bronchitis airway casts. Ann Am Thorac Soc. 2013;10(2):98–107.PubMed PubMedCentral CrossRef
3.Schumacher KR, Stringer KA, Donohue JE, Yu S, Shaver A, Caruthers RL, et al. Fontan-associated protein-losing enteropathy and plastic bronchitis. J Pediatr. 2015.
4.Kunder R, Kunder C, Sun HY, Berry G, Messner A, Frankovich J, et al. Pediatric plastic bronchitis: case report and retrospective comparative analysis of epidemiology and pathology. Case Rep Pulmonol. 2013;2013:649365.PubMed PubMedCentral
5.Brooks K, Caruthers RL, Schumacher KR, Stringer KA. Pharmacotherapy challenges of Fontan-associated plastic bronchitis: a rare pediatric disease. Pharmacotherapy. 2013;33(9):922–34.PubMed PubMedCentral CrossRef
6.Costello JM, Steinhorn D, McColley S, Gerber ME, Kumar SP. Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. Pediatrics. 2002;109(4), e67.PubMed CrossRef
7.Do TB, Chu JM, Berdjis F, Anas NG. Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature. Pediatr Cardiol. 2009;30(3):352–5.PubMed CrossRef
8.Gibb E, Blount R, Lewis N, Nielson D, Church G, Jones K, et al. Management of plastic bronchitis with topical tissue-type plasminogen activator. Pediatrics. 2012;130(2):e446–50.PubMed CrossRef
9.Lubcke NL, Nussbaum VM, Schroth M. Use of aerosolized tissue plasminogen activator in the treatment of plastic bronchitis. Ann Pharmacother. 2013;47(3), e13.PubMed CrossRef
10.Collen D, Lijnen HR, Todd PA, Goa KL. Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs. 1989;38(3):346–88.PubMed CrossRef
11.Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med. 1988;319(14):925–31.PubMed CrossRef
12.Kruithof EK, Dunoyer-Geindre S. Human tissue-type plasminogen activator. Thromb Haemost. 2014;112(2):243–54.PubMed CrossRef
13.Seifried E, Tanswell P, Ellbruck D, Haerer W, Schmidt A. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost. 1989;61(3):497–501.PubMed
14.Seifried E, Tanswell P, Rijken DC, Barrett-Bergshoeff MM, Su CA, Kluft C. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelforschung. 1988;38(3):418–22.PubMed
15.Tanswell P, Heinzel G, Greischel A, Krause J. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. J Pharmacol Exp Ther. 1990;255(1):318–24.PubMed
16.Krippendorff BF, Kuester K, Kloft C, Huisinga W. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn. 2009;36(3):239–60.PubMed PubMedCentral CrossRef
17.Warshawsky I, Bu G, Schwartz AL. LRP and the receptor-mediated endocytosis of plasminogen activators. Ann N Y Acad Sci. 1994;737:70–87.PubMed CrossRef
18.Camani C, Kruithof EK. Clearance receptors for tissue-type plasminogen activator. Int J Hematol. 1994;60(2):97–109.PubMed
19.Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1992;89(16):7427–31.PubMed PubMedCentral CrossRef
20.Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88(3):887–918.PubMed PubMedCentral CrossRef
21.Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 1992;269(3):375–82.PubMed CrossRef
22.Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrinol Metab TEM. 2002;13(2):66–74.PubMed CrossRef
23.Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science New York, NY. 2015;347(6220):1260419.CrossRef
24.Wygrecka M, Wilhelm J, Jablonska E, Zakrzewicz D, Preissner KT, Seeger W, et al. Shedding of low-density lipoprotein receptor-related protein-1 in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;184(4):438–48.PubMed CrossRef
25.Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet. 2011;43(11):1082–90.PubMed CrossRef
26.Meng H, Chen G, Zhang X, Wang Z, Thomas DG, Giordano TJ, et al. Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(8):2426–33.CrossRef
27.Lackowski NP, Pitzer JE, Tobias M, Van Rheen Z, Nayar R, Mosharaff M, et al. Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice. Pulm Pharmacol Ther. 2010;23(2):107–14.PubMed PubMedCentral CrossRef
28.Stringer KA, Tobias M, Dunn JS, Campos J, Van Rheen Z, Mosharraf M, et al. Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice. Clin Exp Pharmacol Physiol. 2008;35(12):1454–60.PubMed PubMedCentral
29.Stringer KA, Racz J, Heath L, Southard S, Lackowski NP, Tsai WC, Caruthers RL. Low expression of low density Lipoprotein Receptor-Related Protein (LRP)-1 in the airway contributes to the slow elimination of lung delivered Tissue Plasminogen Activator (tPA). Am J Respir Crit Care Med. 2011;183.
30.Bauman KA, Wettlaufer SH, Okunishi K, Vannella KM, Stoolman JS, Huang SK, et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest. 2010;120(6):1950–60.PubMed PubMedCentral CrossRef
31.Okunishi K, Sisson TH, Huang SK, Hogaboam CM, Simon RH, Peters-Golden M. Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. J Biol Chem. 2011;286(37):32231–43.PubMed PubMedCentral CrossRef
32.Millien VO, Lu W, Mak G, Yuan X, Knight JM, Porter P, et al. Airway fibrinogenolysis and the initiation of allergic inflammation. Ann Am Thorac Soc. 2014;11 Suppl 5:S277–83.PubMed PubMedCentral CrossRef
33.Corti M, Brody AR, Harrison JH. Isolation and primary culture of murine alveolar type II cells. Am J Respir Cell Mol Biol. 1996;14(4):309–15.PubMed CrossRef
34.Ballinger MN, Newstead MW, Zeng X, Bhan U, Horowitz JC, Moore BB, et al. TLR signaling prevents hyperoxia-induced lung injury by protecting the alveolar epithelium from oxidant-mediated death. J Immunol (Baltim Md: 1950). 2012;189(1):356–64.CrossRef
35.Chen J, Chen Z, Narasaraju T, Jin N, Liu L. Isolation of highly pure alveolar epithelial type I and type II cells from rat lungs. Lab Investig. 2004;84(6):727–35.PubMed CrossRef
36.Dunn JS, Nayar R, Campos J, Hybertson BM, Zhou Y, Manning MC, et al. Feasibility of tissue plasminogen activator formulated for pulmonary delivery. Pharm Res. 2005;22(10):1700–7.PubMed PubMedCentral CrossRef
37.Foster WM, Walters DM, Longphre M, Macri K, Miller LM. Methodology for the measurement of mucociliary function in the mouse by scintigraphy. J Appl Physiol. 2001;90(3):1111–7.PubMed
38.Sakamoto A, Matsumaru T, Yamamura N, Suzuki S, Uchida Y, Tachikawa M, et al. Drug transporter protein quantification of immortalized human lung cell lines derived from tracheobronchial epithelial cells (Calu-3 and BEAS2-B), bronchiolar-alveolar cells (NCI-H292 and NCI-H441), and alveolar type II-like cells (A549) by liquid chromatography-tandem mass spectrometry. J Pharm Sci. 2015.
39.Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, et al. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23:S71–87.PubMed CrossRef
40.Takano M, Kawami M, Aoki A, Yumoto R. Receptor-mediated endocytosis of macromolecules and strategy to enhance their transport in alveolar epithelial cells. Expert Opin Drug Deliv. 2014;1–13.
41.Biessen EA, van Teijlingen M, Vietsch H, Barrett-Bergshoeff MM, Bijsterbosch MK, Rijken DC, et al. Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation. 1997;95(1):46–52.PubMed CrossRef
42.Luo M, Hajjar KA. Annexin A2 system in human biology: cell surface and beyond. Semin Thromb Hemost. 2013;39(4):338–46.PubMed CrossRef
43.Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006;281(4):2120–7.PubMed CrossRef
44.Lin L, Wu C, Hu K. Tissue plasminogen activator activates NF-kappaB through a pathway involving annexin A2/CD11b and integrin-linked kinase. J Am Soc Nephrol JASN. 2012;23(8):1329–38.PubMed CrossRef
45.Mantuano E, Lam MS, Gonias SL. LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein. J Biol Chem. 2013;288(47):34009–18.PubMed PubMedCentral CrossRef
46.Liu Z, Ma Y, Moyer MP, Zhang P, Shi C, Qin H. Involvement of the mannose receptor and p38 mitogen-activated protein kinase signaling pathway of the microdomain of the integral membrane protein after enteropathogenic Escherichia coli infection. Infect Immun. 2012;80(4):1343–50.PubMed PubMedCentral CrossRef
47.Hastings RH, Folkesson HG, Matthay MA. Mechanisms of alveolar protein clearance in the intact lung. Am J Physiol Lung Cell Mol Physiol. 2004;286(4):L679–89.PubMed CrossRef
48.Dobbs LG, Johnson MD. Alveolar epithelial transport in the adult lung. Respir Physiol Neurobiol. 2007;159(3):283–300.PubMed CrossRef
49.Santos Cavaiola T, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014;36(8):1275–89.PubMed CrossRef
50.Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S5–S23.PubMed CrossRef
51.Hickey AJ. Back to the future: inhaled drug products. J Pharm Sci. 2013;102(4):1165–72.PubMed CrossRef
52.Zhang C, An J, Strickland DK, Yepes M. The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain. Am J Pathol. 2009;174(2):586–94.PubMed PubMedCentral CrossRef
53.Nilsson A, Vesterlund L, Oldenborg PA. Macrophage expression of LRP1, a receptor for apoptotic cells and unopsonized erythrocytes, can be regulated by glucocorticoids. Biochem Biophys Res Commun. 2012;417(4):1304–9.PubMed CrossRef - 作者单位：Swan Lin (1)
Jennifer Racz (1)
Melissa F. Tai (1)
Kristina M. Brooks (1)
Phillip Rzeczycki (2)
Lauren J. Heath (1)
Michael W. Newstead (3)
Theodore J. Standiford (3)
Gus R. Rosania (2)
Kathleen A. Stringer (1)
1. Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA
2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA
3. Division of Pulmonary and Critical Care Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA - 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Pharmacology and Toxicology
Pharmacy
Biochemistry
Medical Law
Biomedical Engineering - 出版者：Springer Netherlands
- ISSN：1573-904X
文摘
Purpose To gain knowledge of lung clearance mechanisms of inhaled tissue plasminogen activator (tPA).